This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
Association of Transdermal Drug Patches with Thermal Burns During Magnetic Resonance Imaging Procedures – Notice to Hospitals
- Starting date:
- April 26, 2005
- Posting date:
- April 26, 2005
- Type of communication:
- Notice to Hospitals
- Subcategory:
- Drugs
- Source of recall:
- Health Canada
- Issue:
- Important Safety Information
- Audience:
- Hospitals
- Identification number:
- RA-170001130
Notice about Health Canada advisories
Health Canada Endorsed Important Safety Information on Magnetic Resonance Imaging Systems
April 26, 2005
To: Hospital Chief of Medical Staff
Please distribute to the relevant Departments of Radiology and Pharmacy and other involved professional staff and post this NOTICE in your institution.
Subject: Association of transdermal drug patches with thermal burns during magnetic resonance imaging procedures
Health Canada is aware of international reports of patient injury associated with the use of transdermal medication patches during magnetic resonance imaging (MRI) procedures. Although no similar incidents have been reported in Canada, this notice is being issued to increase awareness of this problem and provide relevant recommendations.
Transdermal drug patches are adhesive patches used to deliver a dose of drug through the skin at a controlled rate over a period of time. Some transdermal patches contain an aluminum or foil backing in the layer farthest from the skin. This backing helps to contain the drug in the patch's reservoir while it is slowly administered transdermally.Footnote 1
MRI systems produce radio wave pulses of energy. If conductive materials are placed in the MRI field, a concentration of electrical currents sufficient to cause excessive tissue heating could be induced. Though the metallic components found in some transdermal patches are not ferromagnetic, they are conductive and this led to patient burns during MRI procedures in the incidents reported internationally.Footnote 2
In light of this information, Health Canada recommends the following:
- improve professional awareness of this issue by reviewing this information with appropriate staff members,
- ensure that pre-MRI patient screening information includes a specific question related to the use of transdermal drug patches,
- unless it is certain that the patch does not contain conductive material, patients using transdermal patches should be advised to remove their patch prior to the MRI scan; if there are any concerns about the interruption of transdermal drug delivery or the replacement of the patch, the healthcare professional who prescribed the medication should be contacted.
Health Canada depends on health care professionals to report adverse incidents related to medical devices. Any serious and/or unexpected adverse incident related to medical devices should be reported to Health Canada at the following address:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 3002C
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675
For other inquiries, please refer to contact information:
Marketed Health Products Directorate (MHPD)
MHPD_DPSC@hc-sc.gc.ca
Tel/Tél: (613) 954-6522
Fax/Télé: (613) 952-7738
The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada web site.
References
- Footnote 1
-
Karch AM. Don't Get Burnt by the MRI. Am J Nurs 2004; 104(8): 31.
- Footnote 2
-
ISMP Medication Safety Alert. April 8, 2004.